Seeking Alpha

BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS

NEW YORK, Feb. 23, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has ...
FierceBiotech

BrainStorm's ALS cell therapy resoundingly rejected by FDA advisers

FDA advisers were unmistakable in their assessment of BrainStorm Cell Therapeutics’ treatment for amyotrophic lateral sclerosis (ALS): there's just no evidence it works. Members of the Cellular, ...
Seeking Alpha

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

NEW YORK, April 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc (BCLI). (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...